United Cannabis Corporation (OTC:CNAB) just announced that they have formed an advisory board "to help the Company advance and protect the development of its proprietary formulations, including managing the clinical trial process, patent protection, new product research and development, as well as identifying and pursuing potential strategic relationships."
The first appointed member of CNAB's advisory board is Dr. Brent A. Reynolds, Ph.D. Dr. Reynolds served United Cannabis as Chief Medical Advisor since 2014, and also served at United Cannabis' Director of Discovery Research & Development.
Dr Reynolds received his Ph.D. from the University of Calgary where he co-discovered the presence of stem cells in the brains of adult mammals. Prior to joining United Cannabis Corp. Dr. Reynolds co-founded NeuroSpheres, Ltd, "where he developed a patent portfolio and protocols related to the application of neural stem cells to treating disorders of the central nervous system."
Dr. Reynolds will be a key member of the newly formed advisory board for United Cannabis' cannabinoid therapy program.
For more information and recent coverage on United Cannabis Corp., be sure to check out the company's stock profile in our rapidly growing marijuana stocks database. For United Cannabis' press release regarding the advisory board, click here.